YILING PHARMACEUTICAL(SZ:002603) Xin Lang Cai Jing·2025-11-14 02:31Group 1 - Yiling Pharmaceutical's stock increased by 5.29%, reaching 21.49 CNY per share, with a trading volume of 1.012 billion CNY and a turnover rate of 3.50%, resulting in a total market capitalization of 35.903 billion CNY [1] - The company, established on August 28, 2001, and listed on July 28, 2011, is located in the High-tech Industrial Development Zone of Shijiazhuang, Hebei Province, focusing on the research, production, and sales of traditional Chinese medicine [1] - The revenue composition of Yiling Pharmaceutical includes cardiovascular products at 48.60%, respiratory system products at 22.80%, other products at 22.52%, and patented products at 6.08% [1] Group 2 - Huatai-PineBridge Fund has one fund heavily invested in Yiling Pharmaceutical, with a reduction of 11,000 shares in the third quarter, holding a total of 150,200 shares, which accounts for 3.25% of the fund's net value, ranking as the eighth largest holding [2] - The fund, established on July 26, 2022, has a current size of 73.3687 million CNY, with a year-to-date return of 3.17%, ranking 4132 out of 4216 in its category, and a one-year loss of 3.9%, ranking 3883 out of 3955 [2] - The fund manager, Chen Kehan, has been in position for 114 days, overseeing total assets of 2.226 billion CNY, with the best return during the tenure at 2.93% and the worst at -7.96% [2]